AU Patent

AU2020217402B2 — Neuroactive steroid formulations and methods of treating CNS disorders

Assigned to Sage Therapeutics Inc · Expires 2023-11-23 · 2y expired

What this patent protects

Formulations comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a p-cyclodextrin, e.g., a sulfo butyl ether p-cyclodextrin, e.g., CAPTISOL@; and methods of use in treating CNS disorders.

USPTO Abstract

Formulations comprising a neuroactive steroid, e.g., allopregnanolone; and optionally a cyclodextrin, e.g., a p-cyclodextrin, e.g., a sulfo butyl ether p-cyclodextrin, e.g., CAPTISOL@; and methods of use in treating CNS disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020217402B2
Jurisdiction
AU
Classification
—
Expires
2023-11-23
Drug substance claim
No
Drug product claim
No
Assignee
Sage Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.